Skip to main content

NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Clinical Trials Using Cabozantinib

Review the clinical trials studying cabozantinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 30

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy with or without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Status: Active
Location: 454 locations
Testing the Addition of Stereotactic Radiation Therapy with Immune Therapy for the Treatment of Patients with Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Status: Active
Location: 304 locations
Study of Targeted Therapy vs. Chemotherapy in Patients with Thyroid Cancer
Status: Active
Location: 292 locations
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
Status: Active
Location: 250 locations
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults with Advanced Adrenocortical Cancer
Status: Active
Location: 81 locations
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status: Active
Location: 50 locations
Comparing Retreatment of 177Lu-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Status: Active
Location: 33 locations
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients with Autoimmune Disorders, AIM-NIVO
Status: Active
Location: 42 locations
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Status: Active
Location: 13 locations
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Status: Active
Location: 9 locations
Altering the Selection and Timing of Therapies for the Treatment of Widely Metastatic Ewing Sarcoma and CIC-Rearranged Sarcoma
Status: Active
Location: 10 locations
Cabozantinib-s-malate in Treating Patients with Non-small Cell Lung Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Location: 8 locations
Abemaciclib and Cabozantinib for the Treatment of Stage IV Clear Cell or Translocation-Associated Renal Cell Carcinoma in Patients Refractory to Immune Checkpoint Blockade Treatment
Status: Active
Location: 8 locations
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Status: Active
Location: 6 locations
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Status: Active
Location: 5 locations
Alternate Cabozantinib Dosing Schedule Alone and in Combination with Nivolumab for the Treatment of Metastatic Kidney Cancer and Neuroendocrine Tumors
Status: Active
Location: 5 locations
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Status: Active
Location: 5 locations
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Status: Active
Location: 4 locations
Cabozantinib Plus High-Dose Ifosfamide for the Treatment of Relapsed or Refractory Ewing Sarcoma and Osteosarcoma, CaIRS Trial
Status: Active
Location: 3 locations
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults with Recurrent or Metastatic Osteosarcoma, TACOS Study
Status: Active
Location: 2 locations
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
High Dose Cabozantinib for the Treatment of Locally Advanced, Unresectable, or Metastatic Progressive Renal Cell Carcinoma, The Seq-Cabo Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Nivolumab, Ipilimumab, and Cabozantinib for the Treatment of Untreated Renal Cell Carcinoma with Brain Metastases
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Radiation Treatment (Therasphere) in Combination with Systemic Therapy for the Treatment of Advanced Hepatocellular Carcinoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Cabozantinib plus Dostarlimab for Treatment of Recurrent Gynecologic Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama